06:36 EDT Telix Pharmaceuticals (TLX) up 11% to $11.70 after collaboration with Regeneron (REGN)
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Telix Pharmaceuticals, Regeneron announce radiopharma collaboration
- Regeneron, Sanofi announce European Commission approval for Dupixent indication
- Regeneron price target raised to $796 from $769 at Morgan Stanley
- Regeneron price target lowered to $921 from $925 at Bernstein
- Regeneron price target raised to $779 from $765 at RBC Capital